Fractures While Taking Fosamax

In October 2010, the U.S. Food and Drug Administration (FDA) updated the label on Fosamax and other bisphosphonates to include the risk of atypical fractures. The agency has published a review in the New England Journal of Medicine after analyzing data from 2,342 post-menopausal women, concluding that there is little evidence to support the use of bisphosphonates for longer than five years.

Another recent study published in the Archives of Internal Medicine examined the risks of femur fractures with bisphosphonate therapy by comparing patients with atypical femur fractures versus classic fractures. Overall, the researchers found that 82 percent of the atypical femur fracture group had been taking bisphosphonates.

July 19, 2012 in Fosamax | Permalink | Comments (0)

Rare Fractures Linked To Drugs For Weak Bones : NPR

Schneider was one of the first women to suffer from one of these unusual fractures among patients who've been taking osteoporosis drugs called bisphosphonates for years. Or at least her case was one of the first reported in a medical journal, back in early 2006.

Since then, orthopedic surgeons and bone specialists have been seeing more of these unusual fractures among long-term users of bisphosphonate drugs such as Fosamax, Actonel, Boniva and Reclast.

There have been conflicting studies about the possible association between long-term use of such drugs and the risk of atypical fractures. The latest and largest study, a Canadian report published last week in the Journal of the American Medical Association, suggests that women who've been on bisphosphonates for more than five years have a nearly three times higher risk of the unusual fractures than those with only transient exposures to the drugs.

"Although the number of fractures, these unusual fractures, was pretty small — they're pretty rare — (the study) nonetheless did show a relationship with longer-term use," says Dr. Gillian Hawker of St. Michael's Hospital in Toronto, an osteoporosis specialist and study author.


Schneider has led an effort to restrict the use of the bone drug Fosamax, saying extended use can lead to femur fractures like the one she had in 2001.  Other Osteoperosis drugs include Actonel, Boniva and Reclast

March 27, 2012 in Actonel, Boniva, Fosamax, Reclast | Permalink | Comments (0)